CATT Study Update
Thanks to a reliable (but unofficial) source, I have learned that the people running the CATT study (Comparison of Age-Related Macular Degeneration Treatments Trials) have scheduled a meeting for September, and hope to get the study underway shortly thereafter (by late Fall).
The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) is a set of multicenter, randomized clinical trials of treatments for neovascular age-related macular degeneration (AMD), the leading cause of blindness in the United States. The Lucentis-Avastin Trial, supported by the National Eye Institute will be the first CATT clinical trial.
The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) is a set of multicenter, randomized clinical trials of treatments for neovascular age-related macular degeneration (AMD), the leading cause of blindness in the United States. The Lucentis-Avastin Trial, supported by the National Eye Institute will be the first CATT clinical trial.
Irv Arons
posted by Irv Arons @ 3:52 PM
2 comments
2 Comments:
Are there any trials comparing Lucentis with Avantis for the treatment of proliferative diabetic retinopathy or are any being planned?
Dan Roberts of the MD Forum found one study -- "Bevacizumab Versus Ranibizumab for Diabetic Retinopathy", sponsored by The Medical University of Vienna, and started in October 2007. Here is the link: http://tinyurl.com/bdvnaw
I hope this is of some help.
Irv Arons
Post a Comment
<< Home